Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06809374

Enrollment

100

Registered

2025-02-05

Start date

2015-01-01

Completion date

2024-12-31

Last updated

2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer Resectable

Brief summary

Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.

Interventions

DRUGgemcitabine

neoadjuvant therapy for resectable pancreatic cancer using gemcitabine +S1 or gemcitabine + nab-Paxitaxel

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* radiologically resectable pancreatic cancer patients

Exclusion criteria

* a body weight loss of greater than 10% during the six months prior to surgery, the presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal, or heart disease

Design outcomes

Primary

Measure	Time frame
Investigating the Presence of Occult Metastatic Lesions Detected During Neoadjuvant Therapy.	within 6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026